When Mounjaro (tirzepatide) arrived on the scene, it didn't just challenge semaglutide — it outperformed it in head-to-head clinical data. Both are GLP-1 medications, but they work differently and have distinct clinical profiles. Here's everything you need to know to understand which might be the right choice for your weight loss journey.
1The Key Difference: Single vs. Dual Mechanism
Semaglutide is a GLP-1 receptor agonist — it mimics one hormone. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it simultaneously activates two pathways: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that influences energy storage and fat metabolism. Activating both pathways produces synergistic weight loss effects.
Think of it this way: semaglutide turns down your hunger dial. Tirzepatide turns down hunger AND improves how your body handles the calories you do consume. This dual action is why the weight loss numbers are consistently higher.
2Comparing the Clinical Trial Data
In the SURMOUNT-1 trial, tirzepatide at the highest dose (15mg) produced an average weight loss of 22.5% of body weight at 72 weeks. At 5mg and 10mg doses, results were 15% and 19.5% respectively. These numbers exceed what was seen in the STEP trials for semaglutide.
The SURMOUNT-2 trial, conducted specifically in people with type 2 diabetes, showed 15.7% weight loss with tirzepatide — again outperforming comparable semaglutide data in the same population. The SURPASS-CVOT trial also demonstrated cardiovascular risk reduction with tirzepatide.
3Side Effects: How Do They Compare?
Both medications share a similar side effect profile dominated by GI symptoms. Nausea, diarrhea, and vomiting are the most common complaints during dose escalation. In the SURMOUNT-1 trial, nausea occurred in approximately 32% of tirzepatide patients vs. 44% in semaglutide STEP trials — suggesting tirzepatide may be slightly better tolerated GI-wise, though direct comparison trials are limited.
Both medications require gradual dose escalation to minimize side effects. Tirzepatide follows a similar ramp-up protocol, starting at 2.5mg weekly and increasing every 4 weeks. Neither medication is appropriate during pregnancy or for those with certain thyroid conditions.
4Cost and Availability in the USA
Both Wegovy and Mounjaro carry significant list prices in the USA, typically ranging from $900–$1,400 per month without insurance coverage. However, manufacturer savings programs, insurance coverage for eligible patients, and our competitive pricing through licensed pharmacy partners can substantially reduce out-of-pocket costs.
Through Weight Loss Solutions, Wegovy starts from $99.00 and Mounjaro from $176.00. These prices reflect our partnerships with accredited pharmacy networks. A licensed physician must review your case before either medication can be dispensed.
5Which One Should You Choose?
If maximum weight loss is the priority and you have no contraindications to either, tirzepatide (Mounjaro) currently shows superior efficacy in clinical trials. However, semaglutide has a longer track record, more long-term safety data, and is often the first choice for patients who prefer starting with the most studied option.
The right choice depends on your medical history, other medications, insurance coverage, and personal preferences. Your licensed physician will make a recommendation based on your individual profile during the consultation.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a licensed US healthcare provider to determine which medication is appropriate for your individual situation.
